Abbott Laboratories (ABT)
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
5 Defensive Stocks to Buy for a Safe Portfolio Amid Tariff-Led Mayhem
Five defensive stocks to buy at this soaring volatility are TAP, CNP, WEC, BSX, HCA.
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Reasons to Add ABT Stock to Your Portfolio Right Now
Investors feel optimistic about Abbott's robust strength in the EPD, Diabetes and Nutrition businesses. However, unfavorable forex impacts are concerning.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
ABT Stock to Gain From Early CE Mark Approval of Volt PFA System
Abbott achieves early CE Mark approval for the Volt PFA system.
ABT Stock Gains Following the Positive TRILUMINATE Trial Results
Abbott presents positive TRILUMINATE Pivotal trial data, which demonstrates TriClip system's safety and effectiveness at the ACC.25.
Abbott (ABT) Outperforms Broader Market: What You Need to Know
In the latest trading session, Abbott (ABT) closed at $132.65, marking a +1.4% move from the previous day.
Why Abbott Laboratories Stock Leaped by Almost 4% on Thursday
Abbott Laboratories (ABT 4.02%) stock was in fine health on the second-to-last trading day of the week, thanks to news from Europe. Investors greeted this positively, rewarding the company with a share price gain on the day that approached 4%.
ABT Stock to Gain From FDA IDE Approval for Its Coronary IVL System
Abbott's Coronary IVL System wins FDA IDE nod, offering a potential new treatment for arterial calcium blockages.
Abbott (ABT) Increases Yet Falls Behind Market: What Investors Need to Know
Abbott (ABT) reachead $127.21 at the closing of the latest trading day, reflecting a +0.69% change compared to its last close.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
